Status:
COMPLETED
Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.
Eligibility Criteria
Inclusion
- Patients must have probable Alzheimer's disease of mild or moderate severity.
- A brain scan and laboratory results must be consistent with Alzheimer's disease.
- The patient must be otherwise medically healthy.
Exclusion
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
512 Patients enrolled
Trial Details
Trial ID
NCT00074529
Start Date
October 1 2003
End Date
January 1 2006
Last Update
July 24 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.